Publication:
Risperidone attenuates brain damage after focal cerebral ischemia in vivo

dc.contributor.authorYıldız, Ayşegül
dc.contributor.authorGüzel, Orkide
dc.contributor.authorKılıç, Erdinç
dc.contributor.authorSchaebitz, Wolf Ruediger
dc.contributor.authorKılıç, Ertuğrul
dc.contributor.buuauthorYulug, Burak
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentNöroloji Ana Bilim Dalı
dc.date.accessioned2021-09-14T07:55:24Z
dc.date.available2021-09-14T07:55:24Z
dc.date.issued2006-05-31
dc.description.abstractSince their introduction, atypical neuroleptic agents have been discovered to have some beneficial effects beyond their effectiveness as neuroleptic drugs. Among these initially unexpected effects are their potential effects as mood stabilizers in bipolar disorder and their efficacy in improving long-term outcome in schizophrenia. These effects recently raised the question whether these drugs may also have some neuroprotective effect in the brain. To examine this matter, in this study we evaluated the neuroprotective effect of risperidone after permanent focal cerebral ischemia. Anaesthetized male C57BL/6j mice were submitted to permanent thread occlusion of the middle cerebral artery (MCA). Risperidone (0.1, 1 or 10 mg/kg) or vehicle was applied intraperitoneally just after permanent ischemia. Twenty-four hours after permanent ischemia, brain injury was evaluated by triphenyltetrazolium, chloride staining (TTC). Risperidone (0.1, 1 and 10 mg/kg) showed significant neuroprotection after permanent focal cerebral ischemia.
dc.identifier.citationYulug, B. vd. (2006). ''Risperidone attenuates brain damage after focal cerebral ischemia in vivo''. Brain Research Bulletin, 69(6), 656-659.
dc.identifier.endpage659
dc.identifier.issn0361-9230
dc.identifier.issn1873-2747
dc.identifier.issue6
dc.identifier.pubmed16716834
dc.identifier.scopus2-s2.0-33646571947
dc.identifier.startpage656
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0361923006001110
dc.identifier.urihttps://doi.org/10.1016/j.brainresbull.2006.03.017
dc.identifier.urihttp://hdl.handle.net/11452/21925
dc.identifier.volume69
dc.identifier.wos000238180400010
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherPergamon-Elsevier Science
dc.relation.collaborationYurt içi
dc.relation.collaborationYurt dışı
dc.relation.journalBrain Research Bulletin
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNeurosciences & neurology
dc.subjectStroke
dc.subjectRisperidone
dc.subjectNeuroprotection
dc.subjectCerebral ischemia
dc.subjectAcid
dc.subjectProtein
dc.subjectSchizophrenia
dc.subjectStroke
dc.subjectRat
dc.subjectMessenger-rna
dc.subjectStriatal dopamine
dc.subjectEarly intervention
dc.subjectIncomplete ischemia
dc.subjectLong-term morbidity
dc.subject.scopusCommon Carotid Artery; Fluoro Jade; Gerbillinae
dc.subject.wosNeurosciences
dc.titleRisperidone attenuates brain damage after focal cerebral ischemia in vivo
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Nöroloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: